LRRK2 and Parkinson disease: Elevated inflammatory mediators have been observed in LRRK2 mutation carriers16, and increased LRRK2 expression in both innate and adaptive immune cells in PD correlates with enhanced cytokine production17, suggesting that heightened LRRK2 kinase activity may drive proinflammatory responses18.